Search Media Items

A summary of clinical trial results showing that nivolumab (Opdivo®) improved overall survival compared with standard chemotherapy in patients with head and neck squamous cell carcinoma.

Explanations about what cancer is, how cancer cells differ from normal cells, and genetic changes that cause cancer to grow and spread.

In this phase I clinical trial, HIV-positive patients receiving combination antiretroviral therapy who have cancer that has recurred after or has not responded to previous treatment will receive the immune checkpoint inhibitor pembrolizumab.

This Childhood Cancer Genomics summary provides a brief synopsis of current knowledge about the genomic landscape of specific childhood cancers. Get detailed information about various genetic alterations and precision medicine concepts in childhood cancers in this summary for clinicians.

The RAS Initiative facilitates connections between and among researchers, bringing new ideas and technologies to bear on RAS. A guiding principle for these collaborations is close coordination with the activities at the Frederick National Laboratory for Cancer Research (FNLCR) Hub, so that new efforts can have a maximum amount of leverage on each other.

Research grants are subject to many requirements from a variety of legal authorities, with the broadest being the U.S. Constitution.

The Food and Drug Administration has approved more than two dozen drugs to treat childhood cancers. Data from NCI-sponsored clinical trials were used to support the approvals of nearly half of those drugs.

The Early Onset Malignancies Initiative studies the genomic basis of six cancers that develop at an earlier age, occur in higher rates, and are typically more aggressive in certain minority populations.

NCI’s Center for Cancer Genomics uses computational cancer genomics to derive insight about cancer genes and pathways using big data.

NCI's Center for Cancer Genomics uses functional genomics to understand the impact of cancer genes and pathways, and how to target them effectively.